SciVision Biotech Inc. (1786) AI Stock Analysis

SciVision Biotech Inc.

(TWSE:1786)

Select Model

Rating:61Neutral

Price Target:TWD 50.00▼(-1.19% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score of 61 reflects a company with a fortress-like balance sheet and attractive dividend yield, offset by significant operational headwinds. The primary concern is the severe revenue contraction and near-total collapse in free cash flow in 2025, which calls the sustainability of the dividend and recent profitability into question. The stock's technical posture is weak, trading well below its long-term averages, though a short-term bounce is underway. The secure financial footing provides a buffer, but the deteriorating earnings trend is the dominant factor capping the score.

Positive Factors

Strong gross-margin structurePersistently high gross margins indicate that the company’s products retain meaningful economic value and pricing or cost advantages. This provides a durable base for profitability and gives management room to fund development and commercialization, even when revenue growth fluctuates.

Negative Factors

Sharp revenue contractionThe abrupt 2025 revenue decline represents a material operational reset and raises questions about the durability of recent demand and commercialization performance. Unless growth recovers, a smaller revenue base can weaken operating leverage, reduce development capacity, and pressure future earnings.

SciVision Biotech Inc. (1786) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.69B
Dividend Yield: 3.77%
Average Volume (3M): 454.41K
Price to Earnings (P/E): 26.1
Beta (1Y): 0.41
Revenue Growth: -2.25%
EPS Growth: -15.57%
Country: TW
Employees: 1,947
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

SciVision Biotech Inc. Business Overview & Revenue Model

Company Description

SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also in...

SciVision Biotech Inc. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong with low leverage (D/E 0.24) and growing equity. However, a sharp 42.8% revenue decline in 2025 has pressured margins and caused an 84.6% collapse in free cash flow, significantly offsetting the company's historically robust profitability.

Income Statement

65Positive

Balance Sheet

78Positive

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	870.41M	886.62M	883.31M	712.99M	557.35M	505.54M
Gross Profit	603.29M	638.39M	655.68M	512.49M	371.87M	341.84M
EBITDA	229.17M	270.35M	362.50M	281.35M	238.28M	177.27M
Net Income	142.82M	162.34M	242.25M	177.90M	141.72M	101.72M
Balance Sheet
Total Assets	2.49B	2.67B	2.35B	2.16B	2.10B	2.26B
Cash, Cash Equivalents and Short-Term Investments	871.11M	1.05B	871.43M	804.06M	673.89M	695.84M
Total Debt	485.56M	485.13M	224.24M	347.91M	416.05M	635.37M
Total Liabilities	692.60M	689.35M	457.43M	533.66M	587.30M	812.06M
Stockholders Equity	1.79B	1.98B	1.90B	1.63B	1.51B	1.45B
Cash Flow
Free Cash Flow	78.10M	22.46M	234.99M	257.17M	163.24M	72.73M
Operating Cash Flow	97.37M	123.99M	269.87M	272.01M	178.21M	98.51M
Investing Cash Flow	-138.65M	-142.74M	97.52M	-213.37M	49.59M	-77.00M
Financing Cash Flow	-277.78M	158.53M	-172.52M	-134.53M	-299.71M	240.06M

SciVision Biotech Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1786 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1777	76Outperform	TWD 3.33B	9.20	―	5.26%	-1.07%	10.62%
TW:1783	76Outperform	TWD 3.21B	9.38	―	5.55%	8.14%	29.28%
TW:1786	61Neutral	TWD 3.67B	26.08	―	3.77%	-2.25%	-15.57%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4120	40Underperform	TWD 3.89B	-6.54	―	9.20%	4.35%	-17.92%

* General Sector Average

Performance Comparison

TW:1786 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1786	SciVision Biotech Inc.	50.60	-23.88	-32.06%
TW:1777	SYN-TECH Chemical & Pharmaceutical Co. Ltd.	76.10	3.66	5.06%
TW:1783	Maxigen Biotech Inc.	36.00	-6.30	-14.89%
TW:4120	Orient Europharma Co., Ltd.	43.50	1.61	3.84%
TW:6838	Formosa Pharmaceuticals, Inc.	20.75	-6.05	-22.57%
TW:6885	BRIM Biotechnology, Inc.	29.10	0.20	0.69%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

SciVision Biotech Inc. AI Stock Analysis